Reply: Based on the available randomized trial patients should say no to glutathione for Parkinson's disease

Authors

  • Michael S. Okun MD,

    Corresponding author
    1. Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
    • Department of Neurology, McKnight Brain Institute, University of Florida, Gainesville, Florida, USA
    Search for more papers by this author
  • Anthony Lang MD,

    1. Toronto Western Hospital, Movement Disorders Center, University of Toronto and University Health Network, Toronto, Ontario, Canada
    Search for more papers by this author
  • Joseph Jankovic MD

    1. Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, Texas, USA
    Search for more papers by this author

  • Potential conflict of interest: None reported

No abstract is available for this article.

Ancillary